In this point, treatment with GLP-1 mimetic agents, including DPP-4 inhibitors and GLP-1 analogs, may be a novel therapeutic strategy for patients with not only diabetes but also MetS and atherosclerosis-prone conditions. This evidence concerns the gene DPP4 and metabolic syndrome.